Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.31 |
| ▸ | SRC | P12931 | 2/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22388539 | 0.88 | CNR2 (0.36) | APP | |
| SCHEMBL26596996 | 0.82 | PIK3CB (0.34) | SRC | |
| SCHEMBL18125589 | 0.82 | KCNH2 (0.33) | — | |
| SCHEMBL26014245 | 0.82 | IRAK4 (0.35) | APP | |
| SCHEMBL26853977 | 0.81 | BRD4 (0.38) | GLO1 | |
| SCHEMBL18852736 | 0.80 | PARP1 (0.35) | — | |
| SCHEMBL26433112 | 0.78 | CDK4 (0.33) | — | |
| SCHEMBL26433102 | 0.78 | ABL1 (0.33) | ABL1 | |
| SCHEMBL22388585 | 0.77 | — | — | |
| SCHEMBL5021603 | 0.74 | MKNK2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200224234-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS OF USE IN VIVO THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2020-07-16 | — | — | US | disclosed |
| US-20190218257-A1 | NOVEL NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218257-A1 | NOVEL NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | SLC35B2, SLC29A2, PNP | APP 3839/4885GSK3B 4091/4885GLO1 2397/4885 |
| US-20200224234-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS OF USE IN VIVO THEREOF | NUDT1, DNTT, TRMT1 | APP 1991/4885GSK3B 4233/4885GLO1 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.